絞り込み

16644

広告

がん種類別・ステージ別 5年生存率の詳細データ (NHK)

国立がん研究センターが発表した、5年生存率のがんの種類・ステージ別のデータは以下のとおりです。全体の生存率が高い順に示します。 前立腺がん ▽ステージ1=100...

  1. がん 5年生存率 全体で66.4% 最高...
  2. 首位アジルバがオルメテックを大きく突き放...
  3. 【動画】この薬を食前に飲んで下さい。 (...
  4. 遺伝性乳がん 予防切除、保険適用 中医協...

ニュース一覧

スターを付ける スターを付ける     (1view , 0users)

Full Text Sources

Miscellaneous

Precursor T-cell lymphoblastic neoplasms are aggressive malignancies in need for more effective and specific therapeutic treatments. A significant fraction of these neoplasms harbor deletions on the locus 9p21, targeting the tumor suppressor CDKN2A but also deleting the aconitase 1 gene (ACO1), a neighboring housekeeping gene involved in cytoplasm and mitochondrial metabolism. Here we show that reducing the aconitase activity with fluorocitrate decreases the viability of T-cell lymphoblastic neoplasia cells in correlation to the differential aconitase expression. The consequences of the treatment were evidenced in vitro using T-cell lymphoblastic neoplasia cell lines exhibiting 9p21 deletions and variable levels of ACO1 expression or activity. Similar results were observed in melanoma cell lines, suggesting a true potential for fluorocitrate in different cancer types. Notably, ectopic expression of ACO1 alleviated the susceptibility of cell lines to fluorocitrate and, conversely, knockdown experiments increased susceptibility of resistant cell lines. These findings were confirmed in vivo on athymic nude-mice by using tumor xenografts derived from two T-cell lines with different levels of ACO1. Taken together, our results indicate that the non-targeted ACO1 deficiency induced by common deletions exerts a collateral cellular lethality that can be used as a novel therapeutic strategy in the treatment of several types of cancer.
PMID: 31734690 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード